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Abstract
Background: A recently licensed pneumococcal conjugate vaccine has been shown to be highly
effective in the prevention of bacteremia in immunized children but the degree of protection against
pneumonia has been difficult to determine.
Methods: We sought to develop a model of Streptococcus pneumoniae pneumonia in Sprague-
Dawley rats. We challenged three-week old Sprague-Dawley pups via intrapulmonary injection of
S. pneumoniae serotypes 3 and 6B. Outcomes included bacteremia, mortality as well histologic
sections of the lungs.
Results: Pneumonia was reliably produced in animals receiving either 10 or 100 cfu of type 3
pneumococci, with 30% and 50% mortality respectively. Similarly, with type 6B, the likelihood of
pneumonia increased with the inoculum, as did the mortality rate. Prophylactic administration of a
preparation of high-titered anticapsular antibody prevented the development of type 3 pneumonia
and death.
Conclusion: We propose that this model may be useful for the evaluation of vaccines for the
prevention of pneumococcal pneumonia.
Background
Streptococcus pneumoniae is the leading cause of bacterial
pneumonia in children and adults in both developing and
developed countries. In the United States, S. pneumoniae
accounts for about 500,000 cases of pneumonia each year
[1]. The recent dramatic rise in the prevalence of clinical
isolates that are multi-drug resistant raises the possibility
that antibiotic therapy may become less effective in treat-
ing pneumococcal disease. At the same time, the institu-
tion of universal immunization with polysaccharide-
protein conjugates in the United States offers the promise
of significant reduction in the number of cases of invasive
pneumococcal disease [2]. The extent to which conjugate
vaccines will have an impact on mucosal and respiratory
pneumococcal disease, however, is less certain. Data from
the Kaiser Permanente Northern California vaccine trials
and phase IV studies suggest a significant reduction in the
frequency of clinically-diagnosed as well as radiologically-
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confirmed pneumonia [2,3]. Due to the difficulties inher-
ent in the diagnosis of pneumonia, however, these data
must be interpreted with caution.
In addition, because the distribution of serotypes respon-
sible for pneumococcal pneumonia is not as well charac-
terized as for bacteremic disease, the spectrum of coverage
provided by conjugate vaccines may be narrower for non-
bacteremic pneumonia than for bacteremic illness. This is
particularly relevant in the developing world, where pneu-
mococcal serotypes responsible for both invasive and
mucosal disease differs from that in industrialized coun-
tries [4].
Current animal models of pneumococcal disease have
several limitations. Not all serotypes are reliably patho-
genic in mice and most models require very high inocula
to cause disease. In addition, existing animal models of
invasive pneumococcal disease are highly virulent and
depend on outcomes such as bacteremia, sepsis and mor-
tality [5-8]. These models, with the exception of the chin-
chilla otitis media model [9], therefore may not be
appropriate for the evaluation of vaccines for the preven-
tion of nonbacteremic or mucosal pneumococcal disease.
In this study we sought to develop a model of focal pneu-
mococcal pneumonia in young rats. In addition, we
hypothesized that pretreatment with anticapsular pneu-
mococcal antibody would prevent pulmonary pathology
in this model.
Methods
Bacteriologic methods
Strains of Streptococcus pneumoniae were originally
obtained from the collections of Drs. George Siber
(Wyeth-Lederle Vaccine and Pediatrics, Pearl River, NY)
and David Briles (University of Alabama, Birmingham)
and passaged through rats via intraperitoneal challenge as
described previously [7]. Passaged strains were stored in
either skim milk or Todd-Hewitt broth supplemented
with 0.5% yeast extract (Difco Laboratories, Detroit, MI)
and 20% glycerol at -70°C, and fresh subcultures were
used for all experiments. Inocula for animal challenge
were prepared by growing Streptococcus pneumoniae to
mid-log phase (approximately 107 CFU/ml) in 10 ml of
Todd-Hewitt broth supplemented with 0.5% yeast extract.
The suspension was diluted in 0.5% low melting-point
agarose (as an adjuvant [7]) to a desired inoculum con-
centration. The number of cfus delivered in the inocula-
tion was calculated the following day based on the
dilutions made from the mid-log phase culture.
Animal model
Outbred virus-free Sprague-Dawley rats were obtained
from Charles River Laboratories, Wilmington, MA. Preg-
nant female rats were quarantined 4 to 5 days prior to
delivery of a litter. On day 4 post delivery, infant pups
from all litters were randomly redistributed so that each
mother had 10–12 pups. Animals weaned at about three
weeks of life, after which the dam was removed and the
litter rats were distributed in cages of six animals each.
Intrathoracic inoculations were performed in the follow-
ing fashion. The right chest of each 3-week-old rat was
prepared with alcohol, and a 0.05 ml inoculum was
injected transthoracically into the mid-right lung via a 29-
gauge needle on an insulin syringe. The depth of the
intrathoracic injection was controlled by a small hemostat
clipped at the base of the needle. Following the injection,
animals were observed for the presence of any distress that
may signify the development of a pneumothorax. Ani-
mals that appeared ill immediately after the injection
were sacrificed.
In a second series of experiments, animals were randomly
assigned to receive either 1 cc of bacterial polysaccharide
immune globulin (BPIG) or normal saline intraperito-
neally, administered 24 hours prior to bacterial challenge.
BPIG is a hyperimmune serum obtained from adults
immunized with 23-valent pneumococcal vaccine, Hae-
mophilus influenzae type b conjugate vaccine and Neisseria
meningitidis polysaccharide vaccine and consists predomi-
nantly of IgG, with trace amounts of IgA and IgM. Out-
comes following intrathoracic injection were compared
between the two groups (see below).
Outcomes
Mortality was assessed for 7 days after inoculation. Bacter-
emia was assessed on days 1 and 4 after inoculation. The
distal dorsal tail vein of each unanesthetized pup was
cleansed with 70% alcohol and punctured with a sterile
lancet and 0.01 ml of blood was spread on 5% sheep's
blood agar. Plates were incubated overnight at 37°C, and
colonies were counted the following morning. The lower
limit of detection of bacteremia was 100 cfu/ml.
Randomly selected animals were sacrificed on days 2 and
4 following challenge for lung culture and assessment of
lung histopathology. Lung microbiology and histopathol-
ogy specimens were obtained from randomly selected ani-
mals sacrificed on day 2 and 4 following intrathoracic
challenge. Lung cultures were obtained using sterile tech-
niques. Lungs were dissected en bloc from the thorax,
transported in sterile vials, and then homogenized using a
Tissue Tearor (Biospec Products, Inc., Bartlesville, OK).
Lung cultures were performed on blood agar plates sup-
plemented with gentamicin (2.5 mg/L) to suppress the
growth of normal oral flora. Lung specimens were also
obtained for histologic examination. Formalin (10%) was
instilled via tracheal instillation via a 20-gaugeJournal of Immune Based Therapies and Vaccines 2004, 2 http://www.jibtherapies.com/content/2/1/2
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intravenous catheter immediately upon dissection. An
animal was considered as having had pneumonia if any
area of polymorphonuclear infiltration or infiltrative con-
solidation of lung parenchyma was seen under 100X.
Experimental procedures for use with animals were
reviewed and approved by the Children's Hospital Animal
Care and Use Committee, and were in keeping with the
guidelines of the National Institutes of Health.
Results
Virulence is dependent on serotype and inoculum size 
(Table 1)
In our initial experiments, we used a strain of S. pneumo-
niae serotype 3, which was found to be highly virulent in
a previously published infant rat model of invasive pneu-
mococcal disease [7]. An inoculum of 10 or 100 cfu relia-
bly produced pneumonia in 100% of animals. This
serotype was highly virulent; death occurred in 3/10 and
5/10 animals, with inocula of 10 and 100 cfu respectively.
While we did not assay for bacteremia in this subset of
animals, we found in pilot experiments that the presence
of bacteremia was a highly reliable predictor of mortality
in this model (data not shown).
Given the high virulence of type 3 in this model, we next
studied a strain of serotype 6B. The aim of these experi-
ments was to select a strain and inoculum size that would
cause pneumonia without bacteremia or death. Using
inocula ranging from 103 to 106 colony-forming units
(cfu) per 0.05 cc (the volume of the intrathoracic injec-
tion), we then examined the frequency with which pneu-
monia developed. Table 1 demonstrates that the
frequency of pneumonia increases with the inoculum
size. This can also be seen with representative histopatho-
logical sections in Figure 1. Bacteremia was only detected
in animals that received the highest inoculum (106 cfu/
dose). Nonbacteremic animals looked clinically well up
to seven days after inoculation. This remained true regard-
less of whether pneumonia was present on histopatholog-
ical examination.
From these experiments, we concluded that a transtho-
racic inoculum of this strain of serotype 6B with 105 cfu
would result in pneumonia in approximately 50% of ani-
mals, without causing bacteremia. Using a similar inocu-
lum with a serotype 19F isolate (106 cfu), pneumonia was
produced in all challenged animals, but was also associ-
ated with 50% bacteremia and mortality.
Pretreatment with bacterial polysaccharide immune 
globulin prevents pneumonia and death (Table 2)
For the following experiments, animals were challenged
intrathoracically with WU-2, a serotype 3 laboratory strain
of S. pneumoniae. Animals that received prophylactic intra-
peritoneal administration of 1 ml BPIG were significantly
less likely to develop pneumonia than animals that
received saline (0/23 vs. 17/30 (57%), p < 0.0001). Mor-
tality was significantly reduced as well in pre-treated ani-
mals (2/30 vs. 14/30, p < 0.001).
Discussion
We have developed a model of focal pneumococcal pneu-
monia in young rats. As has been previously noted in
mouse and infant rat models by different investigators, we
found that the virulence of Streptococcus pneumoniae in our
model is dependent on the serotype. In our model, the
bacterial inoculum necessary to produce pneumonia in
>50% of animals was 100 cfu for WU-2 (serotype 3 strain)
and 105 cfu for a serotype 6B strain, a 1000-fold differ-
ence. By varying the serotype and the inoculum, the fre-
quency of pneumonia and the mortality rate was
correspondingly modified. Of interest, despite the high
virulence of WU-2 in this model, pneumonia and mortal-
ity could still be abrogated by pre-administration of bac-
terial polysaccharide immune globulin.
Previously established animal models of pneumococcal
invasive disease have several disadvantages. The most
Table 1: Effect of serotype and inoculum size on the occurrence of pneumonia, bacteremia, and mortality following intrathoracic 
challenge in rats
Serotype Inoculum (cfu) N % pneumonia % bacteremia % mortality
19 106 10 100 50 50
6B 103 54 0 00
104 63 3 00
105 65 0 00
106 12 75 100 100
3 1 01 01 0 0 N D 3 0
100 10 100 ND 50
ND: not determinedJournal of Immune Based Therapies and Vaccines 2004, 2 http://www.jibtherapies.com/content/2/1/2
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Hematoxylin-Eosin stain preparation of lung sections (original magnification 100×) obtained from autopsied rats following injec- tion with a low (100 cfu per injection, panel A), medium (1000 cfu per injection, panel B) and high (10,000 cfu per injection,  panel C) inoculum of type 6B pneumococcus in 0.5% low melting-point agarose Figure 1
Hematoxylin-Eosin stain preparation of lung sections (original magnification 100×) obtained from autopsied rats following injec-
tion with a low (100 cfu per injection, panel A), medium (1000 cfu per injection, panel B) and high (10,000 cfu per injection, 
panel C) inoculum of type 6B pneumococcus in 0.5% low melting-point agarose. As the size of the inoculum increases, there is 
a clear progression from normal-appearing lung, focal pneumonia and diffuse pneumonia. Shown are 3 slides from a represent-
ative experiment.Journal of Immune Based Therapies and Vaccines 2004, 2 http://www.jibtherapies.com/content/2/1/2
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commonly used model of pneumococcal disease has been
the mouse model [5], in which very high inocula are
required, particularly for higher numbered serotypes,
which are less virulent in the mouse. Furthermore, these
models require intraperitoneal or intravenous routes of
inoculation, which are not representative of the human
route of pulmonary infection. Conversely, we have previ-
ously published data from an infant rat model in which
inocula of different serotypes ranging from 1 to 400 cfu
caused overwhelming pneumonia and sepsis [7]. While
this model has been useful for the determination of min-
imal protective concentrations of anticapsular antibodies
(a range that was subsequently confirmed in the Kaiser
Permanente heptavalent pneumococcal conjugate trial in
California), a legitimate concern is that this model may
result in an underestimation of the protective capacity of
antibodies (whether capsular or other), by virtue of
increased susceptibility of the infant rat to pneumococci.
The data presented here may represent a more physiolog-
ically relevant model of pneumococcal pneumonia. Using
a strain of serotype 6B, we show that at the highest inocu-
lum of 106 cfu per injection, animals develop a fulminant
pneumonia with 100% bacteremia and mortality. In con-
trast, lowering the inoculum (using a range between 103
and 105 cfu per injection), we were able to show that
pneumonia can be reproduced reliably, without concom-
itant bacteremia, sepsis, or high mortality. In sum, we pro-
pose that this model may therefore be more applicable for
the study of the pathophysiology and therapeutic inter-
ventions in nonbacteremic pneumococcal pneumonia
than previously published models.
We previously showed that the onset of bacteremia and
sepsis occurs later in rats challenged via the intrathoracic
route compared to the intraperitoneal route [7]. We also
demonstrated that rats challenged via the intrathoracic
route reliably develop pneumococcal pneumonia, as
demonstrated by an increase in the colony counts from
whole lung tissue cultures. Together, these data suggest
that the initial event leading to disease in these animals is
the establishment of pneumococcal pneumonia, followed
by seeding of the bloodstream and subsequent sepsis.
Recent data suggest that the expression of virulence genes
is phase-variable [10]. Most recently, investigators have
demonstrated that pneumococci grown in peritoneal
fluid express significantly more pneumolysin, a known
intracellular pulmonary toxin, than those cultured in vitro
[11]. It is quite plausible that the expression of different
virulence genes may vary depending on whether the
organism is grown in the lung versus the bloodstream or
peritoneum. Using our model of nonbacteremic pneumo-
coccal pneumonia, an analysis of the virulence genes
expressed during lung infection vs. peritoneal challenge
may provide important information regarding the patho-
physiology of pneumococcal lung disease and the factors
which promote dissemination of pneumococci from the
lung to the bloodstream.
Conclusions
We have developed a model of nonbacteremic pneumo-
coccal pneumonia in the Sprague-Dawley rat. The inocula
in this model range from 102 and 104 cfu per intrathoracic
injection, which are substantially lower than that required
in mouse models of pneumococcal disease. We were able
to utilize this model to demonstrate a protective effect of
anticapsular antibody against pneumonia and death. In
this light, we propose that this model may be useful for
the evaluation of vaccines for the prevention of pneumo-
nia as well as for the study of the pathophysiologic mech-
anisms that lead to the development of pneumonia and
bacteremia.
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